Sugi Predict

Sugi Predict / Compounds / SCHEMBL2722985

SCHEMBL2722985

SCHEMBL2722985

CC(C)(C)OC(=O)NCC1(NC(=O)OCc2ccccc2)CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 5/20 0.54
▸ CTSS P25774 5/20 0.54
▸ CTSB P07858 3/20 0.54
▸ SYK P43405 1/20 0.53
▸ P2RX7 Q99572 1/20 0.48
▸ NPFFR1 Q9GZQ6 1/20 0.48
▸ NPFFR2 Q9Y5X5 1/20 0.48
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ IDO1 P14902 1/20 0.44
▸ CTSK P43235 4/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2722714 0.99 SYK (0.54) CTSLCTSSCTSBSYKP2RX7
SCHEMBL4549859 0.94 SYK (0.51) CTSLCTSSCTSBSYKP2RX7
SCHEMBL14737847 0.94 SYK (0.56) CTSLCTSSCTSBSYKNPFFR1
SCHEMBL14014442 0.89 SYK (0.53) CTSLCTSSCTSBSYKP2RX7
SCHEMBL17596481 0.87 CTSS (0.56) CTSLCTSSCTSBCA12CA1
SCHEMBL17595893 0.85 CTSS (0.54) CTSLCTSSCTSBCA12CA1
SCHEMBL18250355 0.85 CTSS (0.53) CTSLCTSSCTSBSYKNPFFR1
SCHEMBL15585054 0.84 SYK (0.48) CTSLCTSSCTSBSYKP2RX7
SCHEMBL18342224 0.83 SYK (0.50) CTSLCTSSCTSBSYKNPFFR1
SCHEMBL2493576 0.83 CTSS (0.47) CTSLCTSSCTSBSYKCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
US-20240109906-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230248733-A1 HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS G1 THERAPEUTICS, INC. (US) 2023-08-10 — — US disclosed
US-20230248733-A1 HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS G1 THERAPEUTICS, INC. (US) 2023-08-10 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
EP-2632467-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2013-09-04 — — EP disclosed
WO-2012105547-A1 CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF 三菱瓦斯化学株式会社 (JP) 2012-08-09 — — WO disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed
WO-2012057144-A1 CYANATE ESTER COMPOUND, CURABLE RESIN COMPOSITION CONTAINING CYANATE ESTER COMPOUND, AND CURED PRODUCT THEREOF 三菱瓦斯化学株式会社 (JP) 2012-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 CTSL 2084/4885CTSS 2527/4885CTSB 2335/4885
US-20240109906-A1 CDK INHIBITORS CDK3, CDK9, CDK6 CTSL 2084/4885CTSS 2527/4885CTSB 2335/4885
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION RB1, CDK4, CDKN1A CTSL 2899/4885CTSS 2763/4885CTSB 3079/4885
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 CTSL 2542/4885CTSS 3037/4885CTSB 2748/4885
US-20230248733-A1 HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS MKI67, PCNA, HRAS CTSL 1154/4885CTSS 1268/4885CTSB 1044/4885
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY CDK6, CCNC, MCL1 CTSL 1815/4885CTSS 2739/4885CTSB 2580/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 CTSL 2084/4885CTSS 2527/4885CTSB 2335/4885
US-20130237544-A1 CDK INHIBITORS CDK3, CDK9, CDK6 CTSL 2084/4885CTSS 2527/4885CTSB 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.